sub:assertion {
  d:DB00969 v:identifier "DB00969" ;
    v:namespace "drugbank" ;
    v:uri "http://bio2rdf.org/drugbank:DB00969" ;
    v:x-identifiers.org <http://identifiers.org/drugbank/DB00969> ;
    dv:drugbank-id "APRD00580" , "DB00969" ;
    dv:x-atc <http://bio2rdf.org/atc:A03AE01> ;
    dv:x-bindingdb <http://bio2rdf.org/bindingdb:50131429> ;
    dv:x-cas <http://bio2rdf.org/cas:122852-42-0> ;
    dv:x-chebi <http://bio2rdf.org/chebi:253342> ;
    dv:x-chemspider <http://bio2rdf.org/chemspider:2015> ;
    dv:x-gtp <http://bio2rdf.org/gtp:2296> ;
    dv:x-iuphar <http://bio2rdf.org/iuphar:2296> ;
    dv:x-ndc <http://bio2rdf.org/ndc:0173-0738-00> ;
    dv:x-pharmgkb <http://bio2rdf.org/pharmgkb:PA164745502> ;
    dv:x-pubchemcompound <http://bio2rdf.org/pubchem.compound:2099> ;
    dv:x-pubchemsubstance <http://bio2rdf.org/pubchem.substance:46506274> ;
    dv:x-wikipedia <http://bio2rdf.org/wikipedia:Alosetron> ;
    dct:description "Alosetron is a 5-HT3 antagonist used only for the management of severe diarrhoea-predominant irritable bowel syndrome (IBS) in women. Alosetron has an antagonist action on the 5-HT3 receptors and thus may modulate serotonin-sensitive gastrointestinal (GI) processes. Alosetron was voluntarily withdrawn from the US market in November 2000 by the manufacturer due to numerous reports of severe adverse effects including ischemic colitis, severely obstructed or ruptured bowel, and death. In June 2002, the FDA approved a supplemental new drug application allowing the remarketing of the drug under restricted conditions of use."@en ;
    dct:identifier "drugbank:DB00969" ;
    dct:title "Alosetron"@en ;
    a dv:Drug ;
    rdfs:label "Alosetron [drugbank:DB00969]"@en ;
    rdfs:seeAlso <http://www.drugbank.ca/drugs/DB00969> , <http://www.drugs.com/cdi/alosetron.html> , <http://www.rxlist.com/cgi/generic3/alosetron.htm> .
}